Sign in

Alec Machiels

Director at Apellis PharmaceuticalsApellis Pharmaceuticals
Board

About Alec Machiels

Independent director of Apellis since 2009; age 52 as of April 2025. Founding Managing Partner at CoLift LLC (2019–present); prior Partner at Pegasus Capital Advisors (2006–2019; joined 2002). Education: MBA Harvard Business School; License in Law (KU Leuven); MA International Economics (Konstanz University). Designated by the Board as an “audit committee financial expert.”

Past Roles

OrganizationRoleTenureCommittees/Impact
Pegasus Capital Advisors, L.P.Partner2006–2019 (joined 2002)Private equity leadership; board experience across public/private companies (unspecified)
Potentia Pharmaceuticals, Inc.Co‑Founder & CEO2001–2002Potentia was predecessor to Apellis; assets acquired by Apellis in Sep 2015
RevonCo‑Founder2013–2019Healthcare software venture
Goldman SachsFinancial Analyst (FS Group London; Private Equity Group New York)1996–1999Finance/transactions experience

External Roles

OrganizationRoleTenureNotes
CoLift, LLCFounding Managing Partner2019–presentPrivate equity platform
Other boardsDirector (previously)Not specifiedProxy notes prior service on several public/private boards (names not disclosed)

Board Governance

  • Board classification: Class II director; nominated for re‑election at the 2025 Annual Meeting (term to 2028 if elected) .
  • Committees: Audit (Chair), Compensation (Member), Compliance (Member) .
  • Audit committee financial expert designation; committee independence affirmed under Nasdaq/SEC rules .
  • Independence: Board determined all non‑employee directors, including Machiels, are independent (Feb–Apr 2025 review) .
  • Attendance: Board met 7 times in 2024; each director attended ≥75% of board and committee meetings served; independent directors held 5 executive sessions in 2024 .
  • Board leadership: Independent Chair (Gerald Chan); no Lead Independent Director given Chair independence .

Fixed Compensation

  • Director fee structure (2024 program—unchanged for 2025): Board member $50,000; Audit member $12,500 + Audit Chair add’l $12,500; Compensation member $10,000; Compliance member $7,500; Nominating & Governance member $7,500; board chair add’l $33,750 (not applicable to Machiels) .
  • 2024 amounts earned by Machiels:
ComponentAmount ($)
Board retainer50,000
Audit Committee – member12,500
Audit Committee – chair add’l12,500
Compensation Committee – member10,000
Compliance Committee – member7,500
Cash fees total92,500
Option awards (grant-date fair value)199,973
RSU awards (grant-date fair value)199,992
2024 total compensation492,465

Performance Compensation

  • Annual non‑employee director equity program:
    • Jan 2024 grants to each eligible director: Options 5,748; RSUs 3,341; options vest in four quarterly installments within the year (and next Jan 1) and have a 7‑year term; RSUs vest at 1‑year anniversary; change in control vests awards in full .
    • Jan 2025 grants to each eligible director: Options 11,199; RSUs 6,267; same vesting terms; no program changes for 2025 .
Grant DateInstrumentShares/UnitsVestingTerm/Notes
Jan 1, 2024Stock Options5,748 4 equal quarterly installments in 2024 and Jan 1, 2025; service‑based 7‑year term; exercise price = FMV at grant
Jan 1, 2024RSUs3,341 100% on first anniversary (deferral optional) Full acceleration on change in control
Jan 1, 2025Stock Options11,199 4 equal quarterly installments in 2025 and Jan 1, 2026; service‑based 7‑year term; exercise price = FMV at grant
Jan 1, 2025RSUs6,267 100% on first anniversary (deferral optional) Full acceleration on change in control
  • Outstanding awards (as of Dec 31, 2024): Options 216,417; RSUs 6,606 .

Other Directorships & Interlocks

  • Prior board service: “several public and private companies” (not named) .
  • Voting proxy over CEO‑related trust shares: Holds voting proxy for 234,411 shares in The Francois‑DuBois Educational Trust (also listed within CEO’s beneficial ownership), creating an interlock in voting authority with management holdings .
  • Committee interlocks: None disclosed; compensation committee interlocks section indicates no officer/committee cross‑appointments with external entities .

Expertise & Qualifications

  • Financial, legal, and investment background; board experience across public/private companies .
  • Education: MBA (Harvard), License in Law (KU Leuven), MA International Economics (Konstanz) .
  • Audit committee financial expert designation; financial sophistication per Nasdaq rules .

Equity Ownership

  • Beneficial ownership (as of March 31, 2025): 1,229,732 shares (≈1.0% of outstanding); includes:
    • 598,566 shares directly;
    • 250,000 shares held by Bauhaus 1, LLC (wholly owned by a trust of which Machiels is investment trustee);
    • 161,950 shares held by affiliates;
    • 234,411 shares in The Francois‑DuBois Educational Trust (voting proxy held by Machiels);
    • 219,216 shares issuable upon exercise of options exercisable within 60 days .
  • Stock ownership guidelines: Directors must hold ≥3x annual cash retainer; all directors met guidelines at implementation and as of Dec 31, 2024 .
Holder/SourceShares
Direct (Machiels)598,566
Bauhaus 1, LLC (trust where Machiels is investment trustee)250,000
Affiliates161,950
Francois‑DuBois Educational Trust (voting proxy held by Machiels)234,411
Options exercisable ≤60 days219,216
Total beneficial1,229,732 (≈1.0%)

Say‑on‑Pay & Shareholder Feedback

  • 2024 say‑on‑pay support: 89.9% approval of executive compensation .
  • 2023 say‑on‑pay support: >93% approval .

Governance Assessment

  • Strengths

    • Long‑tenured independent director with deep finance/investment background; designated audit committee financial expert; chairs audit committee overseeing financial reporting, risk, compliance, related‑party transactions, and cybersecurity .
    • Independence affirmed; board has independent Chair; regular executive sessions; attendance met board standard (≥75%) .
    • Ownership alignment: meaningful beneficial stake; directors meet stock ownership guidelines .
  • Watch items / RED FLAGS

    • Pledging of Apellis stock: Audit Committee permitted Machiels in 2024 to pledge Company securities as part of a broader collateral package for an extension of credit—pledging is generally discouraged in governance best practice due to potential forced sale risk; monitor scope and any updates to pledging exceptions .
    • Voting proxy interlock: Machiels holds voting proxy over 234,411 shares in a trust associated with CEO’s beneficial ownership, which could create perceived influence over management‑associated votes; monitor for any related‑party considerations or recusal practices .
    • Single‑trigger vesting on change in control for director equity awards (accelerates vesting), which can be viewed as shareholder‑unfriendly by some investors; this is the standard under the director program .
  • Compensation Committee analysis

    • Composition: O’Brien (Chair), Fonteyne, Machiels; Walbert added in March 2025; met six times in 2024 .
    • Consultant: Pay Governance serves as independent compensation consultant; committee assessed independence and found no conflicts, though management also engaged them for broader employee compensation work at committee direction .
    • Director pay: Mixed cash + equity; no meeting fees; annual grants in options and RSUs; program unchanged for 2025 .
  • Related‑party transactions

    • Company maintains formal RPT policy with audit committee review; no director‑specific RPTs disclosed beyond voting proxy note; indemnification agreements standard for directors .

Overall, Machiels brings strong financial oversight as Audit Chair and significant ownership alignment. The 2024 pledge approval and voting proxy over CEO‑related trust shares are notable governance sensitivities; continued transparency and adherence to independence and RPT policies mitigate risk if monitored appropriately.